JP2002509877A5 - - Google Patents

Download PDF

Info

Publication number
JP2002509877A5
JP2002509877A5 JP2000540814A JP2000540814A JP2002509877A5 JP 2002509877 A5 JP2002509877 A5 JP 2002509877A5 JP 2000540814 A JP2000540814 A JP 2000540814A JP 2000540814 A JP2000540814 A JP 2000540814A JP 2002509877 A5 JP2002509877 A5 JP 2002509877A5
Authority
JP
Japan
Prior art keywords
fatty acid
preconcentrate
weight
less
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000540814A
Other languages
English (en)
Japanese (ja)
Other versions
JP4695260B2 (ja
JP2002509877A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/007162 external-priority patent/WO1999049848A1/en
Publication of JP2002509877A publication Critical patent/JP2002509877A/ja
Publication of JP2002509877A5 publication Critical patent/JP2002509877A5/ja
Application granted granted Critical
Publication of JP4695260B2 publication Critical patent/JP4695260B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000540814A 1998-04-01 1999-03-30 抗癌組成物 Expired - Fee Related JP4695260B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8027398P 1998-04-01 1998-04-01
US8027298P 1998-04-01 1998-04-01
US60/080,272 1998-04-01
US60/080,273 1998-04-01
PCT/US1999/007162 WO1999049848A1 (en) 1998-04-01 1999-03-30 Anticancer compositions

Publications (3)

Publication Number Publication Date
JP2002509877A JP2002509877A (ja) 2002-04-02
JP2002509877A5 true JP2002509877A5 (https=) 2006-06-01
JP4695260B2 JP4695260B2 (ja) 2011-06-08

Family

ID=26763305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000540814A Expired - Fee Related JP4695260B2 (ja) 1998-04-01 1999-03-30 抗癌組成物

Country Status (12)

Country Link
EP (1) EP1067908B9 (https=)
JP (1) JP4695260B2 (https=)
KR (1) KR100661879B1 (https=)
CN (1) CN100341485C (https=)
AT (1) ATE327735T1 (https=)
AU (1) AU756752B2 (https=)
CA (1) CA2326485C (https=)
DE (1) DE69931617T2 (https=)
IL (2) IL138767A0 (https=)
SE (1) SE0003449L (https=)
TW (1) TW546152B (https=)
WO (1) WO1999049848A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
KR100615783B1 (ko) * 1997-05-27 2006-08-25 아이박스 리서치 인코포레이티드 탁산 치료를 받고 있는 인체를 제외한 포유동물의 과민증 또는 알러지 반응을 경감시키기 위한 방법 및 약학적 키트
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
EP1479382A1 (en) * 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
AU2006201100B2 (en) * 1999-09-21 2009-09-24 Jagotec Ag Surface modified particulate compositions of biologically active substances
ATE296091T1 (de) * 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
AU7638300A (en) * 1999-10-20 2001-04-30 Vesifact Ag Microemulsion preconcentrates and microemulsions
IL149360A0 (en) * 1999-10-27 2002-11-10 Baker Norton Pharma Method and compositions for administering taxanes orally to human patients
EP1118333A1 (en) * 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions with enhanced oral bioavailability
DE10030378A1 (de) * 2000-06-21 2002-03-14 Audit Inst For Medical Service Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
ATE290372T1 (de) * 2000-07-24 2005-03-15 Upjohn Co Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln
JP2004536026A (ja) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
PT1249231E (pt) * 2001-04-12 2004-06-30 Vesifact Ag Formulacoes farmaceuticas contendo substancias activas anti-inflamatorias e sua utilizacao
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
EP1460992B1 (en) * 2001-12-03 2009-03-11 Dor Biopharma, Inc. Stabilized reverse micelle compositions and uses thereof
JP4526120B2 (ja) * 2002-05-22 2010-08-18 日本製薬株式会社 Ｌ−メントール水中油型乳剤
KR20040008816A (ko) * 2002-07-19 2004-01-31 한미약품 주식회사 파클리탁셀 또는 그의 유도체와 ｐ-당단백질 저해제를함유하는 혈관재협착 방지를 위한 경구투여용 약학 조성물
KR100573289B1 (ko) * 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
DE10247399A1 (de) * 2002-10-08 2004-04-29 Schering Ag Pharmazeutische Zubereitungen, Verwendung dieser Zubereitung und Verfahren zur Erhöhung der Bioverfügbarkeit von peroral zu applizierenden Arzneistoffen
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
WO2005037251A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self-emulsifying drug delivery systems for hydrophobic therapeutic compounds
WO2005037250A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self emulsifying drug delivery systems for hydrophobic therapeutic compounds
NZ549016A (en) 2004-02-13 2012-03-30 Bioavailability Inc A microemulsion preparation of high concentration propofol for anesthetic uses
CA2560298A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Preparation with elevated content
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
CN100361656C (zh) 2004-08-27 2008-01-16 石药集团中奇制药技术（石家庄）有限公司 丁苯酞自乳化释药体系及其制备方法和应用
MX2007011250A (es) * 2005-03-21 2007-11-14 Ivax Pharmaceuticals Sro Inhibidor de la cristalizacion y su uso en capsulas de gelatina.
WO2008058366A1 (en) * 2006-09-28 2008-05-22 Université de Montréal Oil-in-water emulsions, methods of use thereof, methods of preparation thereof and kits thereof
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
CN101785757B (zh) * 2009-01-22 2012-02-22 美迪思生物科技(北京)有限公司 一种紫杉醇自乳化制剂及其制备方法和用途
EP2301523A1 (de) 2009-09-22 2011-03-30 Dr. August Wolff GmbH & Co. KG Arzneimittel Galenische Formulierung in kolloidaler Form
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CN102228431A (zh) * 2010-03-16 2011-11-02 王国强 紫杉烷类化合物的自乳化药物组合物
EA027666B1 (ru) * 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
US20120095098A1 (en) * 2010-10-18 2012-04-19 Bhiku Patel Bioavailability Enhancement Delivery System
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2878311A1 (en) * 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Solubility Enhancement for Hydrophobic Drugs
EP3086777A1 (en) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotril compositions
DE102014015625A1 (de) 2014-10-16 2016-04-21 Gonzalo Urrutia Desmaison Lösungsvermittelnde Zusammenssetzungen
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
EP3326652B1 (en) * 2015-07-30 2021-10-06 Dae Hwa Pharma. Co., Ltd Pharmaceutical composition for oral administration comprising high concentration taxane
TWI838700B (zh) * 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN109589305B (zh) * 2018-12-03 2021-03-19 昆明积大制药股份有限公司 多西他赛-环孢素a共包载自乳化制剂及其制备方法
US20220096376A1 (en) * 2019-01-07 2022-03-31 Pusan National University Industry-University Cooperation Foundation Drug delivery platform using w/o/w-type triolein emulsion promotive of blood-brain barrier opening
PL241264B1 (pl) * 2020-02-19 2022-08-29 Inventionbio Spółka Akcyjna Samoemulsyfikująca kompozycja, przeznaczona do podawania naskórnego, zawierająca biosurfaktant, ko-surfaktant oraz fazę olejową

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680441B2 (en) * 1992-09-22 1997-07-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of taxol for treating lymphomas and breast cancer
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
GB9509321D0 (en) * 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
TW527186B (en) * 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6060518A (en) * 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
PL335891A1 (en) * 1997-03-27 2000-05-22 Baker Norton Pharma Methods of and compositions for treating ovarian carcinoma

Similar Documents

Publication Publication Date Title
JP2002509877A5 (https=)
Maurya et al. Self-micro emulsifying drug delivery systems (SMEDDS): A review on physico-chemical and biopharmaceutical aspects
AU706995B2 (en) Pharmaceutical compositions
JP4695260B2 (ja) 抗癌組成物
US6432445B1 (en) Pharmaceutical capsules comprising a cyclosporin
CN101528196A (zh) 用于生物利用性差的药物的自乳化组合物
LU88138A1 (fr) Nouvelles compositions pharmaceutiques
EP1345590A1 (fr) Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
JP2001525363A (ja) オメガ−３脂肪酸油を含む医薬組成物
JP2002513750A (ja) 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
EP1109532A1 (en) Oral micro-emulsion composition of silybin
KR20040023659A (ko) 장을 통과하는 일차 통과 중에 강한 영향에 견디는 능력이있는 활성 성분을 포함하는 경구용 약학 조성물
CA2471241A1 (en) Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
JP2012067133A (ja) レニン阻害剤を含むマイクロエマルジョン前濃縮物
US9278065B2 (en) Delivery systems for solubilising water-insoluble pharmaceutical active ingredients
KR101928589B1 (ko) 알리스포리비르를 포함하는 제약 조성물
US5189066A (en) Pharmaceutical compositions of tebufelone
Qader et al. Novel Oral Solid Self-Nanoemulsifying Drug Delivery System (S-Snedds) of Rosuvastatin Calcium: Formulation, Characterization, Bioavailability and Pharmacokinetic Study
Hasan et al. Development of potential selfmicroemulsifying lipid formulation for the oral administration of curcumin
EP1848407A2 (en) Oral pharmaceutical composition
EP0431659B1 (en) Pharmaceutical compositions of tebufelone
Hasan Effect of a model lipophilic compound on the phase behaviour of hydrophilic self-micro-emulsifying lipid formulations
JP4734909B2 (ja) 難水溶性薬剤用可溶化剤組成物
NZ516269A (en) Pharmaceutical compositions comprising cyclosporine
WO2019087696A1 (ja) 経口医薬組成物